Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 3NET 2Gastrointestinal 2Dermatologic 1

Conditions

Melanoma 1656Skin Neoplasms 355Lymphoma, T-Cell, Cutaneous 322Carcinoma, Basal Cell 241Mycosis Fungoides 227Sezary Syndrome 209Breast Neoplasms 196Leukemia, Lymphocytic, Chronic, B-Cell 193Lymphoma, Non-Hodgkin 192Lymphoma, Follicular 187Precursor Cell Lymphoblastic Leukemia-Lymphoma 183Lymphoma, Large B-Cell, Diffuse 183Lymphoma, B-Cell, Marginal Zone 182Lymphoma, Mantle-Cell 181Hodgkin Disease 175Lymphoma 174Burkitt Lymphoma 173Uveal Melanoma 170Lymphoma, Large-Cell, Immunoblastic 168Multiple Myeloma 159Keratosis, Actinic 146Neoplasms 142Leukemia, Myeloid, Acute 134Neoplasm Metastasis 125Lymphoma, Large-Cell, Anaplastic 125Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 123Lung Neoplasms 120Immunoblastic Lymphadenopathy 115Leukemia, Myeloid, Accelerated Phase 113Leukemia, Myeloid, Chronic-Phase 112

Interventions

veliparib 1Temozolomide 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Zollinger-Ellison Syndrome × Dermatologic × Clear all
NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Vanderbilt-Ingram Cancer Center

Phase 1 Withdrawn
DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡